Is Bal Pharma overvalued or undervalued?

As of 14 November 2025, Bal Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 18.76, an EV to EBITDA of 10.07, and a Price to Book Value of 1.63, which suggest a favorable valuation relative to its earnings and asset base.
In comparison to its peers, Bal Pharma's PE Ratio is significantly lower than Sun Pharma's 36.49 and Divi's Lab's 69.65, both of which are categorized as expensive. Additionally, its EV to EBITDA is more favorable than that of Torrent Pharma, which stands at 33.11. Despite recent underperformance compared to the Sensex, with a year-to-date return of -34.27% versus the Sensex's 8.22%, Bal Pharma's current valuation metrics indicate it remains an attractive investment opportunity within the pharmaceuticals and biotechnology sector.